Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Decline in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 100 shares, a drop of 95.2% from the March 15th total of 2,100 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 1.0 days. Currently, 0.0% of the shares of the stock are short sold.

Basilea Pharmaceutica Price Performance

Shares of Basilea Pharmaceutica stock remained flat at $51.00 during trading hours on Friday. The company has a 50-day moving average price of $53.04 and a two-hundred day moving average price of $52.84. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10. Basilea Pharmaceutica has a fifty-two week low of $51.00 and a fifty-two week high of $54.00.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.